St. Paul lab markets high-accuracy breast cancer blood test
Astrin Biosciences, a St. Paul diagnostic lab, is marketing Certitude, a new blood test meant to supplement mammograms and improve breast cancer detection, especially for women with dense breast tissue.[1]
Certitude analyzes roughly 7,000 proteins in a small blood sample using mass spectrometry and artificial intelligence.[1] Peer-reviewed studies published by Astrin report cancer-detection accuracy above 90% and false negatives under 1%.[1] Astrin says Certitude is commercially available in 48 states, returns results in a few days, and a similar prostate cancer test is in development.[1]
Astrin began by validating the protein-based approach in studies that were submitted for peer review, aiming to address the limits of mammography in dense breasts.[1]
Show source details & analysis (1 source)
📌 Key Facts
- Astrin Biosciences, based in St. Paul, has developed a breast cancer blood test called Certitude aimed at supplementing mammograms, particularly for women with dense breast tissue.
- The test examines roughly 7,000 proteins in a small blood sample via mass spectrometry and AI analysis, with reported cancer-detection accuracy above 90% and false negatives under 1% in peer‑reviewed studies.
- Certitude is commercially available in 48 states, with results in a few days, and Astrin says a similar prostate cancer test is in development.
📰 Source Timeline (1)
Follow how coverage of this story developed over time